GetGoal-Duo1, GetGoal-L, and GetGoal-L-Asia evaluated the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy ±OADs among patients with T2DM [5–7]. This evidence concerns the gene INS and type 2 diabetes mellitus.